entertainment -WSS

entertainment

author：entertainment 2025-09-30 00:09:32 - browse：7427

Stock illustration of computer and medication — Adobe

Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics, developer of a software-based treatment for diabetes. Click, which did not disclose how much it is paying for the assets, hopes to adapt Better’s tech for use alongside GLP-1 medications.

Better Therapeutics announced in March that it was delisting from the Nasdaq stock exchange and shutting down operations as it sought strategic alternatives. The company had been, since last year, searching for ways to stay afloat as its cash reserves dwindled.

Last, year, Better received Food and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral therapy and had been shown to reduce A1c levels in people with type 2 diabetes. Still, the company has been unable to ramp up significant commercial traction. Better also had a pipeline of other products targeting cardiometabolic conditions, and had made early claims about the benefits of AspyreRx in people taking GLP-1s for diabetes management.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Immune cells and nerve overgrowth may explain recurring UTI pain

hotspot

WSS

Patients, doctors press FTC to beef up hospital merger scrutiny

Patients, doctors press FTC to beef up hospital merger scrutiny

He's 19 months old and has one of the world’s rarest diseases

Readout Newsletter: BridgeBio, Akero, and human embryo models

FDA weighs limits of animal data in assessing artificial wombs

Information blocking fines are now fair game in health care

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Tori Bowie and the unacceptable rates of Black maternal death

Lack of health data on LGBTQ+ people has serious consequences

Wildfire smoke exposes gaps in outdoor worker protections

Microsoft's Peter Lee: Generative AI could help doctors be more human

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Streamlined flu vaccines recommended by FDA advisory panel

Wildfire smoke exposes gaps in outdoor worker protections

Change Healthcare: What is it, why does its cyberattack matter?

United colonoscopy coverage change 'may cost lives,' doctors say

Stem cell biologist probes earliest stages of human development

hotspot

Immune cells and nerve overgrowth may explain recurring UTI pain

'A game

Readout Newsletter: BridgeBio, Akero, and human embryo models

Medicare drug price negotiation continues, as pharma counteroffers

For AI in health care standards, federal regulators join with industry group

Information blocking fines are now fair game in health care

hotspot

hotspot

hotspot

explore